Dihexa
Cognitive & neuro Research only Animal studies
Also called PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
A modified three-amino-acid peptide derived from angiotensin IV, reworked so it resists breakdown and crosses into the brain. It amplifies hepatocyte growth factor signalling through the c-Met receptor, which drives the formation of new connections between neurons.
Why people take it
What studies report
- Reversed learning deficits in a rat model of Alzheimer's disease
- Promoted new dendritic spines and synapses in cultured neurons
- Described in papers as far more potent than BDNF at forming synapses
In practice Unapproved use
- Used in very small amounts by the nootropic community
- More cautious users avoid it over the theoretical cancer risk from growth-factor signalling
Science hasn't caught up: Circulating in nootropic use with no human trials and an unresolved growth-signalling concern.
Reported real-world use, not evidence and not a recommendation.
Worth knowing: Rodent and cell data from a small number of labs, with no human trials. Because it drives growth-factor signalling, the theoretical cancer risk has not been ruled out in long-term studies.
Status: Research compound. Not approved.
- Route
- Oral or injection; reported to cross the blood-brain barrier
- Sequence
- Hexanoyl-Tyr-Ile-Ahx-NH2
- Formula
- C27H44N4O5
- Molecular weight
- 504.7 g/mol
- CAS
- 1401708-83-5
- Available as
- 10 mg
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.